The sector’s funding engine kept running, with multiple large checks signaling investors’ continued appetite for both early clinical and enabling platforms. Archimed closed its MED IV fund at €1.5 billion, positioning the healthcare investor for broad deployment across biopharma products, diagnostics, med tech, and life-science tools. In therapeutics, Encoded Therapeutics added $275 million in a Series F round to support its Dravet syndrome program and scale genetic medicine manufacturing. The financing reinforces demand for repeatable genetic platform capabilities rather than single-program risk alone. Finally, Revvity agreed to acquire Human Cell Design, extending its cell-model and preclinical screening footprint with human pancreatic beta cell models intended to support metabolic and incretin-related discovery work. Closing is expected in Q4 2026. The combined picture: investors are betting on both capital-efficient platform scaling and on technology that can compress discovery-to-preclinical translation for drugmakers.